Search Results - "Figueras‐Nart, I."

Treatment of moderate‐to‐severe atopic dermatitis with dupilumab in real clinical practice: a multicentre, retrospective case series by Armario‐Hita, J.C., Pereyra‐Rodriguez, J., Silvestre, J.F., Ruiz‐Villaverde, R., Valero, A., Izu‐Belloso, R., Jáuregui‐Presa, I., Curto‐Barredo, L., Figueras‐Nart, I., Herranz‐Pinto, P., Herraez‐Herrera, L., Ortiz‐de‐Frutos, F.J., Martinez‐Pilar, L., Sastre, J., Serra‐Baldrich, E.

Get full text

Dupilumab for atopic dermatitis during pregnancy and breastfeeding: Clinical experience in 13 patients by Escolà, H., Figueras‐Nart, I., Bonfill‐Orti, M., Coll Puigserver, N., Martin‐Santiago, A., Rodríguez Serna, M., Sánchez Hernández, M. C., Sanz‐Cabanillas, J. L., Taberner, R., Zaragoza‐Ninet, V., Pujol, R. M., Curto‐Barredo, L.

Get full text

[Translated article] Improving the Management and Follow-up of Atopic Dermatitis: A Delphi Process Report of Consensus Between Hospital Dermatologists and Pharmacists by Herranz-Pinto, P., Figueras Nart, I., Monte-Boquet, E., Tortajada Goitia, B.

“…Managing atopic dermatitis, one of the most common dermatologic conditions, is often challenging. To establish consensus on recommendations for responding to…”
Get full text

Omalizumab updosing allows disease activity control in patients with refractory chronic spontaneous urticaria by Curto‐Barredo, L., Spertino, J., Figueras‐Nart, I., Expósito‐Serrano, V., Guilabert, A., Melé‐Ninot, G., Cubiró, X., Bonfill‐Ortí, M., Garcias‐Ladaria, J., Villar, M., García‐Navarro, X., Bielsa‐Marsol, I., Vilavella, M., Aparicio, G., Baliu‐Piqué, C., Álvarez, A., Lamas‐Domenech, N., Duran‐Jordà, X., Serra‐Baldrich, E., Giménez‐Arnau, A.

Get full text

Defining the actinic keratosis field: a literature review and discussion by Figueras Nart, I., Cerio, R., Dirschka, T., Dréno, B., Lear, J.T., Pellacani, G., Peris, K., Ruiz de Casas, A.

“…Despite the chronic and increasingly prevalent nature of actinic keratosis (AK) and existing evidence supporting assessment of the entire cancerization field…”
Get full text

Improving the Management and Follow-up of Atopic Dermatitis: A Delphi Process Report of Consensus Between Hospital Dermatologists and Pharmacists by Herranz-Pinto, P, Figueras Nart, I, Monte-Boquet, E, Tortajada Goitia, B

“…Managing atopic dermatitis, one of the most common dermatologic conditions, is often challenging. To establish consensus on recommendations for responding to…”
Get full text

Treatment of Severe Atopic Dermatitis With Upadacitinib in Clinical Practice: Short-Term Efficacy and Safety Results by Pereyra-Rodriguez, J J, Herranz, P, Figueras-Nart, I, Perez, B, Elosua, M, Munera-Campos, C, Melgosa-Ramos, J, Zaragoza, V, Silvestre, J F, Campos-Domínguez, M, Guilabert, A, Miquel, J, Alcantara-Luna, S, Serra-Baldrich, E, Armario-Hita, J C

Get full text

Omalizumab for the treatment of chronic inducible urticaria in 80 patients by Exposito‐Serrano, V., Curto‐Barredo, L., Aguilera Peiro, P., Gómez Armayones, S., Serra‐Baldrich, E., Spertino, J., Bonfill Ortí, M., Figueras Nart, I., Melé‐Ninot, G., Baliu‐Piqué, C., Sala Cunill, A., Labrador‐Horrillo, M., Guilabert Vidal, A., Fernández Chico, N., Giménez‐Arnau, A.M.

Get full text

Consensus on the diagnostic algorithm for chronic nodular prurigo by Ortiz de Frutos, J, Serra Baldrich, E, Tribó Boixareu, M J, Armario Hita, J C, Carrascosa Carrillo, J M, Nart, I Figueras, Menéndez, Á Flórez, Pinto, P Herranz, Francisco Silvestre, J

“…Chronic nodular prurigo (CNP) is a chronic dermatological disease characterized by the presence of chronic pruritus and pruritic nodular lesions. The aim of…”
Get full text

Definition of Recurrent Chronic Spontaneous Urticaria by Melé-Ninot, G, Serra-Baldrich, E, Curto-Barredo, L, Figueras-Nart, I, Spertino, J, Expósito-Serrano, V, García-Navarro, X, Guilabert, A, Bielsa-Marsol, I, Giménez-Arnau, A

“…Abstract is missing (Short communication)…”
Get full text

Algorithm for Treatment of Chronic Spontaneous Urticaria with Omalizumab by Spertino, J, Curto Barredo, L, Rozas Muñoz, E, Figueras Nart, I, Gimenez Arnau, A, Serra Baldrich, E, Bonfill-Ortí, M, Expósito-Serrano, V, Guilabert, A, Melé Ninot, G, Villar Buil, M, Garcias Ladaria, J, García Navarro, X, Vilavella, M, Bielsa Marsol, I, Aparicio Ortiz, G, Baliu Piqué, C, Álvarez Abella, A, Lamas Domenech, N, Mascaró, J M, Gómez, S, Torné Gutiérrez, J I, Vicente Villa, A

“…BACKGROUND AND OBJECTIVEPivotal trials with omalizumab for treatment of chronic spontaneous urticaria (CSU) are generally run over 12 to 24weeks. However, in…”
Get full text

Algorithm for Treatment of Chronic Spontaneous Urticaria with Omalizumab by Spertino, J., Curto Barredo, L., Rozas Muñoz, E., Figueras Nart, I., Serra Baldrich, E., Bonfill-Ortí, M., Expósito-Serrano, V., Guilabert, A., Melé Ninot, G., Villar Buil, M., Garcias Ladaria, J., García Navarro, X., Vilavella, M., Bielsa Marsol, I., Aparicio Ortiz, G., Baliu Piqué, C., Álvarez Abella, A., Lamas Domenech, N., Mascaró, J.M., Gómez, S., Torné Gutiérrez, J.I., Vicente Villa, A., Gimenez Arnau, A.

“…Pivotal trials with omalizumab for treatment of chronic spontaneous urticaria (CSU) are generally run over 12 to 24weeks. However, in clinical practice, many…”
Get full text

Classification of the cutaneous manifestations of COVID‐19: a rapid prospective nationwide consensus study in Spain with 375 cases by Galván Casas, C., Català, A., Carretero Hernández, G., Rodríguez‐Jiménez, P., Fernández‐Nieto, D., Rodríguez‐Villa Lario, A., Navarro Fernández, I., Ruiz‐Villaverde, R., Falkenhain‐López, D., Llamas Velasco, M., García‐Gavín, J., Baniandrés, O., González‐Cruz, C., Morillas‐Lahuerta, V., Cubiró, X., Figueras Nart, I., Selda‐Enriquez, G., Romaní, J., Fustà‐Novell, X., Melian‐Olivera, A., Roncero Riesco, M., Burgos‐Blasco, P., Sola Ortigosa, J., Feito Rodriguez, M., García‐Doval, I.

“…Summary Background The cutaneous manifestations of COVID‐19 disease are poorly characterized. Objectives To describe the cutaneous manifestations of COVID‐19…”
Get full text

308 Incremental improvements after switching from dupilumab (DUPI) to upadacitinib (UPA) in the Heads Up open-label extension (OLE) study by Prajapati, V.H., Glick, B., Spelman, L., Figueras Nart, I., Calimlim, B., Ladizinski, B., Wu, T., Liu, Y., Davis, J., Aydin, H., Ehst, B.

Get full text

1542 Allergen sensitization status stratifies IL-31 production by memory T cells in atopic dermatitis by Sans-De San Nicolàs, L., Figueras-Nart, I., García-Jiménez, I., Bonfill-Ortí, M., Guilabert, A., Curto-Barredo, L., Bertolín-Colilla, M., Ferran, M., Serra-Baldrich, E., Pujol, R., Santamaria-Babí, L.

Get full text

053 SEB-induced IL-13 production in CLA+ memory T cells defines Th2 high and Th2 low responders in atopic dermatitis by Sans-De San Nicolàs, L., Figueras-Nart, I., Bonfill-Ortí, M., García-Jiménez, I., Guilabert-Vidal, A., Curto-Barredo, L., Ferran, M., Serra-Baldrich, E., Pujol, R., Santamaria-Babí, L.

Get full text

[Translated article] Consensus on the Diagnostic Algorithm for Chronic Nodular Prurigo by Ortiz de Frutos, J., Serra Baldrich, E., Tribó Boixareu, M.J., Armario Hita, J.C., Carrascosa Carrillo, J.M., Figueras Nart, I., Flórez, Á., Herranz Pinto, P., Francisco Silvestre, J.

Get full text

Baricitinib treatment rapidly improves the four signs of atopic dermatitis assessed by Eczema Area and Severity Index (EASI) clinical subscores by Wollenberg, Andreas, Simon, Dagmar, Kulthanan, Kanokvalai, Figueras‐Nart, Ignasi, Misery, Laurent, Tangsirisap, Nithi, Spina, Lara, Lu, Na, Grond, Susanne, Eyerich, Kilian

“…Background Baricitinib treatment in adults with moderate‐to‐severe atopic dermatitis (AD) has demonstrated rapid improvements in itch as well as AD sign…”
Get full text

Translated article Consensus on the Diagnostic Algorithm for Chronic Nodular Prurigo by Ortiz de Frutos, J, Serra Baldrich, E, Tribó Boixareu, M J, Armario Hita, J C, Carrascosa Carrillo, J M, Figueras Nart, I, Flórez, Á, Herranz Pinto, P, Francisco Silvestre, J

“…Chronic nodular prurigo (CNP) is a chronic dermatological disease characterized by the presence of chronic pruritus and pruritic nodular lesions. The aim of…”
Get full text

Patient-Reported Burden of Severe Alopecia Areata: First Results from the Multinational Alopecia Areata Unmet Need Survey by Bewley, Anthony, Figueras-Nart, Ignasi, Zhang, Jainzhong, Guerreiro, Mariana, Tietz, Nicole, Chtourou, Sami, Durand, Frederick, Blume-Peytavi, Ulrike

“…Alopecia areata (AA) is an autoimmune disease characterized by hair loss that has significant psychosocial implications. This study aims to describe the…”
Get full text